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similarmedication adherence and total medical costs however; exenatide patients
had significantly lower total pharmacy costs.
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OBJECTIVES: To evaluate the cost-effectiveness of alternative renal screening
strategies and implications for blood pressure treatment in patients with type 1
diabetes. This required development of a discrete time simulationmodel for type 1
diabetes patients to estimate quality-adjusted life years (QALYs). METHODS: We
synthesized evidence on type 1 diabetes patients using several published sources.
The simulation model was based on eleven equations to estimate transitions be-
tween health states. Screening identified patients with impaired renal function
whom were then assigned angiotensin-converting enzyme inhibitors (ACE-I) to
lower blood pressure and improve renal function. Screening intervals were varied
from 1 year to 10 yearly intervals and compared to current UK guidelines of annual
screening. Outcomes were expressed in QALYs based on utilities of different dia-
betes complications obtained from a meta-analysis. Costs of the monitoring pro-
gram, treatment and hospitalisation from diabetes-related complications were in-
cluded. 1000 patients (mean age 15 years) were simulated for 85 years and cost-
effectiveness analyses performed. Costs and effects were discounted at standard
rates. Uncertainty surrounding these results was also calculated. RESULTS:When
comparing annual screening to biennial screening, the reduction in the number of
patients on ACE-I reduces both costs and QALYs, showing an incremental cost-
effectiveness (ICER) ratio of £9,718 per QALY. Increasing the screening interval to 5
years resulted in further reductions in both costs and QALYs, and an ICER well
within the National Institute of Health and Clinical Excellence’s (NICE) recom-
mended threshold. Sensitivity analyses showed universal treatment increased
survival rates when compared to annual screening and no treatment by an addi-
tional 4.4 and 5.5 years, respectively. CONCLUSIONS: Renal screening for people
with type 1 diabetes is cost-effective in the UK context compared to other funded
health interventions. Further research is required to determine whether universal
treatment is a policy that is worth pursuing in the long term.
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OBJECTIVES: It is currently estimated that 2 million South Africans suffer from
Type 2 Diabetes. Experts agree that the burden of diabetes is unacceptably high.
Thus access to appropriate treatment is a priority for the country. The objective of
this study was to investigate the cost effectiveness of saxagliptin (Onglyza®), a
DPP-4 inhibitor, plus metformin compared with a sulphonylurea (SU) plus met-
formin (MET) in South African patients not well controlled on metformin alone.
METHODS:Data from a 52 week clinical trial comparing saxagliptin and sulphony-
lurea in combination with metformin was used in a simulation model to estimate
long term complications in a cohort of type 2 diabetes patients. The model esti-
mates the incidence of microvascular andmacrovascular complications, diabetes-
specific mortality, all-cause mortality, and ultimately, costs and quality-adjusted
life years (QALYs) associated with the investigated treatment strategies. Costs and
QALYs were estimated for a lifetime time horizon and discounted at 5%. The per-
spective of private health care funders was used. RESULTS: Compared with SU
MET, the cost per QALY gainedwith saxagliptinMET is approximately ZAR 35,566.
Patients on saxagliptinMET gain 0.1 QALYs on average when compared to SU
MET, at an incremental cost of around ZAR 3775. The cost-effectiveness results
were robust to various sensitivity analyses. The improvement in quality of life was
associated mainly with lower incidence of hypoglycaemic events and modest re-
ductions in both macro and micro vascular complications in the cohort receiving
saxagliptin plus metformin compared with SUMET. CONCLUSIONS: This study
demonstrates that, over a patient’s lifetime, the addition of saxagliptin to met-
formin is associated with improvements in quality-adjusted life years compared
with SU in patients with type 2 diabetes. Saxagliptin treatment is a cost-effective
treatment alternative for type 2 diabetes in patients not well-controlled on met-
formin alone.
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OBJECTIVES: To evaluate the cost-effectiveness of saxagliptin plusmetformin ver-
sus sulfonylurea plus metformin in T2DM patients, who cannot achieve glycemic
goals with metformin monotherapy, in Colombia. METHODS: Cost effectiveness
analysis was performed using a discrete event simulation model with fixed time
steps (Cardiff Diabetes Model). The characteristics of the patients included in this
study and the efficacy profile for each treatment were obtained from the published
literature. The cost of medication was obtained from SISMED and Farmaprecios,
and the macro and microvascular events were based on POS tariffs, SOAT Manual
and consultationwith a local expert. The timehorizonwas 20 years and the applied
discount rate on costs and benefits was 3.5%. One-way and probabilistic sensitivity
analyses were performed for parameters and model assumptions. RESULTS: The
group treated with saxagliptin combination had fewer fatal and nonfatal events
and fewer episodes of hypoglycemia than the sulfonylurea combination popula-
tion. In both treatment groups the costs are driven by drug costs and treatment
costs associated with myocardial infarction. The incremental cost of saxagliptin
combination therapy over 20 years was US$555.552. Treatment with saxagliptin
plusmetformin resulted in a greater number of quality-adjusted life years (QALYs)
and life-years gained (LYG) than the sulfonylurea combination (9.758 vs. 9.504 and
11.786 vs. 11.758 respectively). The cost per QALY gained was US$2190. Cost-effec-
tiveness results were robust to sensitivity analysis. CONCLUSIONS: Considering
the GDP per capita in Colombia (US$6,348), our results suggest that the addition of
saxagliptin tometformin in patientswho do not achieve adequate glycemic control
withmetforminmonotherapy, is highly cost-effective compared with the addition
of sulfonylurea.
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OBJECTIVES:Analog insulin has become increasingly popular despite higher per
unit price compared to human insulin. This study evaluated the cost-effective-
ness of two premixed analog insulin preparations, compared with long-acting
analog insulin (LAAI) and pre-mixed human insulin (PHI) from the perspective
of a UK health care payer.METHODS: The CORE Diabetes Model (IMS Health) was
used to evaluate the cost-effectiveness of biphasic insulin [insulin lispro 75/25
(LM75/25) and 50/50 (LM50/50)] versus LAAI and PHI. Treatment effects were
taken directly from a recent Agency for Healthcare Research and Quality (AHRQ)
meta-analysis, while pharmacy, complication and patient management costs
were taken from published sources, expressed in 2008 pounds sterling. Future
costs and clinical benefits were discounted at 3.5% per annum. Sensitivity anal-
yses included: A1C effect, relative risk (RR) of hypoglycemia, time horizon, dis-
count rate, diabetes treatment and complication costs, and method of quality
adjusted life expectancy estimation. RESULTS: LM75/25 and LM50/50 increased
discounted quality-adjusted life expectancy (QALE) by 0.10 and 0.12 quality-
adjusted life years (QALYs), respectively, and reduced total lifetime direct med-
ical costs (LM75/25:£20,809 LAAI:£22,234; LM50/50:£20,680 LAAI:£21,292), domi-
nating LAAI. Compared to PHI, both LM75/25 and LM50/50 increased QALE (by
0.03 QALYs) and total lifetime direct medical costs (LM75/25/LM50/50:£18,499
PHI:£18,494), resulting in an incremental cost effectiveness ratio of £146/QALY
on a weighted mean A1C benefit of 0.06% in both cases. The only sensitivity
analyses in which LM75/25 and LM50/50 were not cost-effective compared to
LAAI or PHI were those in which the least favorable bound of the 95% confidence
intervals for RR of hypoglycemia or A1C difference were used. CONCLUSIONS:
Based on the findings of the AHRQ meta-analysis, and assuming a cost/QALY
threshold of £30,000/QALY, LM75/25 and LM50/50 would be considered cost-effec-
tive when compared with PHI and dominant when compared with LAAI from the
perspective of the UK health care payer.
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OBJECTIVES: Effective glycemic control can reduce the risk of serious micro- and
macrovascular complications in type 2 diabetes. However, many patients fail to
reach glycemic targets due partly to low efficacy and adverse effects of treatment
(such as hypoglycemia or weight gain). The aim of this analysis was to evaluate the
short-term cost-effectiveness of liraglutide versus sitagliptin, in terms of cost per
patient reaching a glycated hemoglobin (HbA1c) target with no hypoglycemia and
noweight gain after 52-weeks, based on a recently published trial.METHODS:Data
were taken froma randomized, controlled trial (NCT00700817) inwhich adultswith
type 2 diabetes (mean age 55 years, HbA1c 8.4%, BMI 33kg/m2) failing metformin
monotherapy were randomly allocated to receive either 1.2mg liraglutide, 1.8mg
liraglutide or 100mg sitagliptin daily in addition to metformin. For the cost-effec-
tiveness analysis, the proportion of patients achieving a clinically relevant com-
posite endpoint, defined as HbA1c7.0%, with no reported hypoglycemia and no
gain in bodyweight, were estimated using logistic regression. Costs of antidiabetes
medications were accounted based on published wholesale acquisition costs in
2011USdollars ($).RESULTS:Trial data showed that 38.9% of patients on liraglutide
1.2mg and 49.9% on liraglutide 1.8mg achieved the composite endpoint, compared
with 18.6% on sitagliptin. Overall pharmacy costs (needle costs included) were
higher on liraglutide than sitagliptin.When expressed as themean cost per patient
reaching target HbA1c with no hypoglycemia or weight gain (cost of control), costs
were notably lower on liraglutide than on sitagliptin. Annual mean costs of control
were $9,632 on liraglutide 1.2mg and $10,933 on liraglutide 1.8mg, versus $14,711 on
sitagliptin.CONCLUSIONS:Themean cost per patient achieving control, defined as
reaching HbA1c target with no hypoglycemia or weight gain, was lower with lira-
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glutide than with sitagliptin based on data from a recently published 52-week
clinical trial.
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OBJECTIVES: To evaluate the cost effectiveness of pharmacist intervention (the
enhanced care group-ECG) relative to primary care physicians only (control group)
in improving cardiovascular (CVD) outcomes among patients with Type 2 diabetes
mellitus (T2DM). METHODS: Data were collected from medical charts at Kaiser
Permanente (KP) clinics. Patients in the ECG were matched 1:1 to patients in the
control group based on age, gender, HbA1C, and Charlson comorbidity score. The
UKPDS risk engine was used to estimate the 10-year CVD risk. A Markov state-
transitionmodel was developed to simulate the difference in CVD risk between the
two hypothetical cohorts of ECG and control group. The primary outcome was the
incremental cost and effectivenessmeasured by life years and per quality-adjusted
life year (QALY) gained. Sensitivity analysis(SA) was conducted to examine the
robustness of the results. RESULTS: The base case model suggests that the ECG
dominated the control group with lower treatment cost ($35,740 vs. $44,528) per
patient and more life years (8.9 vs.8.1) and QALY (5.51 vs. 5.02) over the 10-year
period. Within the reasonable range of variability of all parameters, however, the
multiple one-way SA revealed that the relative value of ECG depends on the time
horizon adopted by the payers. The probabilistic sensitivity analysis suggests that
when adopting a longer time horizon such as 5 or more years in management, the
ECG has a far higher chance of being chosen as a cost-effective strategy regardless
of the level of willingness to pay. When the time horizon was shortened, however,
the likelihood for the ECG being cost- effective decreased. CONCLUSIONS: Adding
pharmacists to the health care management team for diabetic patients can be a
cost-effective strategy in terms of the improvements in the cardiovascular out-
come achieved over the long term.
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OBJECTIVES: 1) To identify key features of cost-effectiveness analyses (CEAs) of
type 2 diabetes mellitus (T2DM) of the United States (US) population; 2) to assess
the quality of T2DM CEAs; and 3) to identify the predictors of quality. METHODS:
We searched PubMed for several MeSH terms with English language restriction,
through August 2011. The quality of eligible studies was evaluated using the Qual-
ity of Health Economic Evaluation (QHES) instrument. Multiple linear regression
analysis was conducted for the predictors of quality (overall QHES score) and inde-
pendent variables being features of the T2DMCEA literature.RESULTS:A total of 38
full-text articles met inclusion criteria of which: Forty-six percent were pharma-
ceutical companies funded/sponsored, 82% were conducted from healthcare pay-
ers perspective, 77%were published in clinical-focused journals, 85% used quality-
adjusted life-years (QALYs), 79% used published literature as the data source, 28%
used the Center for Outcomes Research diabetes model, 51% were classified as
disease treatment/management, and 64% used more than one-way sensitivity
analysis. Overall, mean quality score using QHES was 73.211.5 and only 51% of
studies scored75 (high-quality). Many studies (69%) failed to describe the analysis
perspective and/or reasons for its selection; whereas, most of the studies (95%)
used valid and reliable health outcomes scales/measures. Multiple linear regres-
sion found the following significant variables (p0.05): journal impact factor
(11.2, CI7.4-14.0), studies using QALY (34.9, CI11.2-48.1), and published
after year 2000 (35.8, CI13.9-48.6). CONCLUSIONS: All studies funded/spon-
sored by a pharmaceutical company concluded the product of that company to be
cost-effective; thismay be indicative of publication bias and/or design bias. Several
studies failed to follow the societal perspective recommendations of the US Panel
on Cost-effectiveness in Health and Medicine, possibly because of preferences of
the funding agency or researcher’s interests. Decisions based on these studies
should consider quality and other key features of the later.
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OBJECTIVES: Pharmacist-provided medication therapy management (MTM) has
been reported to improve patient outcomes in a variety of settings and patient
populations. Yet, little is known about the long-term economic and clinical out-
comes of MTM. Here, we sought to estimate the incremental, lifetime cost-effec-
tiveness of MTM in type 2 diabetes, over usual dispensing care, from a health
payer perspective. METHODS: We constructed a decision-analytic Markov model
with 10 diabetes disease states. A hypothetical cohort of 40-year-old patients were
followed for the rest of their life expectancy (31 years). Transition probabilities
were derived from the validated CDC-RTI diabetes model. Costs (in 2010 dollars)
associated with each disease state were derived from the ADA’s 2007 report on
diabetes costs. In the base case, MTMwas assumed to increase annual, per-patient
direct medical costs by 1.7%, which is a median of values retrieved from the liter-
ature. Glycemic levels reported under MTMwere used to model the corresponding
effects on the risks for microvascular complications via an exponential parametric
form (Eastman 1997). Risk reduction for coronary heart disease under MTM was
taken from the Fremantle Diabetes Trial. The primary outcome of the model is the
incremental cost per quality-adjusted life-years (QALYs) gained. Future costs and
QALYs were discounted at 3% per annum. Sensitivity analyses were undertaken to
assess model robustness and uncertainties. RESULTS: Over usual care, MTMwas
estimated to result in an additional 0.44 QALYs, and in lifetime cost savings of
approximately $20,000 per patient. MTM appeared to improve survival by 4%. Our
estimates are robust to plausible variations in key parameters, and are most sen-
sitive to the probability of nephropathy, and to the effect of MTM on costs.
CONCLUSIONS: Our results suggest that MTM dominates usual care. The increase
in direct medical costs associated with MTM appears to be offset by large cost
savings due to reduction in diabetes-related morbidity and mortality.
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OBJECTIVES: To determine the cost-utility of pregabalin (PRE) vs. duloxetine (DUL)
over a 6 month time horizon from the perspective of US third-party payers using a
decision tree analysis.METHODS: Literature searches identified clinical trials and
real-world studies reporting the efficacy, tolerability, safety, adherence, opioid us-
age, and healthcare utilization and costs of PRE and DUL. The proportions of pa-
tients reported in the included studies were used to determine probabilities in the
decision tree model. Average wholesale price was used to determine the costs of
medications. The costs associated with healthcare utilization were determined
from observational studies and all costs were adjusted to 2011 US dollars. Utility
values formoderate to severe andmild painwere determined fromEuroQoL scores.
The overall utility values were determined by multiplying the utility values by the
disutility values associatedwith adverse events. The base-casemodel included the
FDA approved doses of PRE (300 mg/day) and DUL (60 mg/day) while “real-world”
sensitivity analyses explored the effects over a range of doses (PRE 75-600 mg/day,
DUL 20-120 mg/day). Monte Carlo simulations with 1000 repetitions were used to
perform probabilistic sensitivity analyses (PSA) to examine uncertainty of the es-
timates used in the model. Outcomes from the model were expressed as cost per
quality adjusted life-year (QALY). RESULTS: In the base-case model DUL cost less
and was more effective than PRE (incremental cost -$187, incremental effective-
ness 0.011 QALYs). Results from the real-world sensitivity analyses indicated that
DUL was $16,000 and $20,667 more per QALY than PRE. Cost-effectiveness accept-
ability curves showed that DUL has a higher probability of being cost-effective,
except at very lowwillingness-to-pay thresholds. CONCLUSIONS:Using a decision
tree model that incorporated both clinical trial and real-world data, DUL was a
more cost-effective option than PRE in the treatment of PDN from the perspective
of third-party payers.
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OBJECTIVES: To estimate health care costs and utilization for Medicare beneficia-
ries with type 1 or type 2 diabetes and matched control cohorts. METHODS: We
used a retrospective claims cohort analysis to assess the direct healthcare cost and
utilization of health services in 2009 for patients aged 65 to 89 enrolled in a Medi-
care Advantage plus prescription drug plan. Patients were matched 1:1 with non-
diabetes patients. All-cause health care costs for 2009were calculated as the sumof
all medical and pharmacy claims, and costs directly attributable to diabetes were
evaluated for case cohorts. RESULTS: Our analysis included 6,562 type 1 cases and
the same number of matched controls, and 194,775 type 2 cases and their matched
controls. There were no significant demographic differences between cohorts for
matched variables. Type 2 cases had significantly higher mean Deyo-Charlson Co-
morbidity Index compared to controls (2.47 versus 0.77; p.001), although all
groups had high prevalence of expensive comorbidities such as hypertension
and heart disease. Mean all-cause healthcare costs per patient per year were
significantly higher for type 1 and type 2 cases versus controls for in-patient
hospitalization, outpatient, office, ER visits, pharmacy and total health care
costs (total 2009 costs: type 1 $20,701$30,201, type 1 controls $6,537$10,441,
type 2 $10,437$18,518, type 2 controls $6,505$11,140). The mean diabetes
attributable total health care cost for type 1 and type 2 cohorts were $9,443 
$15,665 and $3,616  $9,229, respectively, per patient per year. CONCLUSIONS:
Diabetes escalates health care costs for Medicare Advantage patients in compari-
son to those without the disease regardless of comorbidities.
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OBJECTIVES: To build a flexible and comprehensive long term Type-1 diabetes
model incorporating themost up-to-date methodologies (e.g. capturing parameter
uncertainty, timeprofile of patient characteristics and including patient behaviour)
to allow a number of cost-effectiveness evaluations.METHODS: An individual pa-
tient level discrete event simulationmodel which includes all the major complica-
tions (nephropathy, neuropathy, retinopathy, CVD, PVD, hypoglycaemia, ketoaci-
dosis) and their interactions along with the treatment effects was built based on
the developed conceptual model. Patient characteristics (demographics, clinical
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